Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Traws Pharma (TRAW) Net Income towards Common Stockholders (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with -$3.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income towards Common Stockholders rose 59.52% to -$3.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$9.6 million, a 74.56% increase, with the full-year FY2024 number at -$54.7 million, down 188.55% from a year prior.
  • Net Income towards Common Stockholders was -$3.0 million for Q3 2025 at Traws Pharma, down from -$223000.0 in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of $15.1 million in Q1 2025 to a low of -$21.4 million in Q4 2024.
  • A 5-year average of -$5.2 million and a median of -$4.6 million in 2023 define the central range for Net Income towards Common Stockholders.
  • Peak YoY movement for Net Income towards Common Stockholders: crashed 380.03% in 2024, then skyrocketed 402.69% in 2025.
  • Traws Pharma's Net Income towards Common Stockholders stood at -$3.8 million in 2021, then crashed by 52.38% to -$5.7 million in 2022, then increased by 22.18% to -$4.5 million in 2023, then plummeted by 380.03% to -$21.4 million in 2024, then surged by 85.83% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Net Income towards Common Stockholders are -$3.0 million (Q3 2025), -$223000.0 (Q2 2025), and $15.1 million (Q1 2025).